-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 25, U.
On April 25, U.
NKX019 is a CD19-targeting CAR-NK cell therapy from Nkarta and a "universal" CAR-NK cell therapy
Lymphoma leukemia high-dose (10x10 8 CAR-NK cells, 3 infusions) group, of 6 evaluable patients: 5 achieved objective response (ORR=83%), 3 achieved complete response (CR=50%) , including one patient with diffuse large B-cell lymphoma and one patient with mantle cell tumor
Likewise, no dose-limiting toxicities, as well as adverse events similar to the side effects of CAR-T
CAR-T
leaves a message here